Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: A population-based study

The Lancet Oncology

Volumn 13, Issue 12, 2012, Pages 1203-1209

  Rengan, Ramesh ^a   Mitra, Nandita ^a   Liao, Kaijun ^a   Armstrong, Katrina ^a   Vachani, Anil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, NON-SMALL-CELL LUNG; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84870242296     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70466-7     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
3. Ginsberg RJ, Rubinstein LV Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615-622.
4. Curran W, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer (NSCLC): randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
7. Postmus PE, Scagliotti G, Groen HJM, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial. Eur J Cancer 1996, 32A:1498-1503.
8. Bradley J, Schild S, Bogart J, et al. RTOG 0617: a randomized phase iii comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/- cetuximab in patients with stage IIIA/IIIB non-small cell lung cancer. Annual Proceedings of the ASTRO Annual Meeting, 2011. Abstract number LB2.
9. Persad GC, Little RF, Grady C Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008, 26:1027-1032.
10. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
11. Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW Merkel cell carcinoma and HIV infection. Lancet 2002, 359:497-498.
12. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004, 36:861-868.
13. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006, 108:3786-3791.
14. Frisch M, Biggar RJ, Engels EA, Goedert JJ Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001, 285:1736-1745.
15. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
16. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006, 24:1383-1388.
17. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005, 39:293-299.
18. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006, 43:47-55.
19. Makinson A, Tenon JC, Eymard-Duvernay S, et al. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011, 6:1022-1029.
20. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012, 118:164-172.
21. Lohse N, Hansen AB, Gerstoft J, Obel N Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007, 60:461-463.
22. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
23. Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 2010, 5:562-571.
24. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002, 40(8 suppl):IV-19-IV-25.
25. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40(8 suppl):IV-3-IV-18.
26. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507.
27. Rosenbaum PR, Rubin D The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
28. D'Agostino R Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
29. Rubin DB Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
30. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002, 136:349-357.
31. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
32. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edn). Chest 2007, 132(3 suppl):234S-242S.
33. Mountain CF, Dresler CM Regional lymph node classification for lung cancer staging. Chest 1997, 111:1718-1723.
34. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer 2000, 88:563-569.
35. Spina M, Sandri S, Serraino D, et al. Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. Ann Oncol 1999, 10:87-90.
36. Bearz A, Vaccher E, Talamini R, Berretta M, Tirelli U Comment on 'Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer 2012, 106:1899-1900.
37. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 2010, 303:1625-1631.
38. Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol 2012, 30:2725-2730.
39. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels E Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2012, published online Oct 17. 10.1097/QAD.0b013e32835ad56e.
40. Althoff KN, Buchacz K, Hall HI, et al. US trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-Infected persons, 2000 to 2008. Ann Intern Med 2012, 157:325-335.
41. Rudek MA, Flexner C, Ambinder RF Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011, 12:905-912.
42. Mitra N, Heitjan DF Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Stat Med 2007, 26:1398-1414.
43. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012, 26:1017-1025.
44. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475-1482.
45. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010, 376:449-457.